Introduction: In the phase III CheckMate 017 study, nivolumab prolonged overall survival versus docetaxel in previously treated patients with advanced squamous NSCLC. Study objectives included health-related quality of life (HRQoL) and symptom assessments.
Introduction
Lung cancer remains the leading cause of cancerrelated deaths. 1, 2 More than 80% of lung cancers are NSCLC and 25% to 30% of NSCLC cases are squamous cell carcinoma. 3, 4 Historically, patients with squamous NSCLC whose disease progresses after first-line platinum-based chemotherapy have been challenging to treat, as they have fewer therapeutic options compared with patients with nonsquamous NSCLC. The standardof-care second-line treatment has typically been docetaxel. 5 Nivolumab, an anti-programmed death 1 antibody, is approved in many countries to treat patients with advanced NSCLC, regardless of histologic type, after prior platinum-based chemotherapy. 6, 7 Approval by the U.S. Food and Drug Administration on March 4, 2015, for squamous NSCLC was based on the phase III CheckMate 017 study, which showed that nivolumab prolonged overall survival (OS) and had a favorable safety profile compared with docetaxel in this population. 8 Improving health-related quality of life (HRQoL) is a priority for patients with lung cancer and their physicians, especially given the highly symptomatic nature of this malignancy. 9 Assessment of patient-reported outcomes (PROs) in cancer trials is valuable for understanding individual symptom benefits, impact on HRQoL, and the balance of potential risks with treatment. 10 Improved HRQoL has been reported with nivolumab in solid tumors. 11, 12 Few studies have reported on HRQoL in the second-line NSCLC setting, and none has evaluated patients with the squamous histologic type specifically. [13] [14] [15] [16] [17] [18] [19] In CheckMate 017, HRQoL was analyzed by using the validated, patient-reported Lung Cancer Symptom Scale (LCSS) and the European Quality of Life Five Dimensions (EQ-5D) questionnaires. We report the impact of nivolumab and docetaxel on HRQoL and symptoms in patients with squamous NSCLC.
Methods

Study Design
CheckMate 017 (NCT01642004) was an international, randomized, open-label, phase III study comparing nivolumab (3 mg/kg intravenously every 2 weeks) with docetaxel (75 mg/m 2 intravenously every 3 weeks) in patients with advanced squamous NSCLC with disease progression during or after one prior platinumcontaining chemotherapy regimen. 8 Full study details have been previously reported. 8 The proportion of patients exhibiting disease-related symptom improvement by week 12, as measured by the LCSS, was a secondary end point. Evaluation of overall health status using the EQ-5D utility index and visual analog scale (VAS) was an exploratory objective.
HRQoL Assessments
The LCSS, a lung cancer-specific PRO instrument, measures six major disease-associated symptoms (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain) and three global items (symptom distress, interference with activity level, and HRQoL). [20] [21] [22] [23] The EQ-5D, a PRO instrument assessing general health status rather than cancer, measures five dimensions (mobility, selfcare, usual activities, pain/discomfort, and anxiety/ depression). [24] [25] [26] Completion of Questionnaires. Patients were asked to complete the LCSS (electronic LCSS-QL 27 ) and EQ-5D questionnaires before study procedures by using an electronic tablet at baseline, on day 1 of every other cycle (every 4 weeks) in the nivolumab group and on day 1 of every cycle (every 3 weeks) in the docetaxel group for the first 6 months of treatment, every 6 weeks thereafter, and at two follow-up visits after treatment discontinuation. Subsequently, EQ-5D assessments continued every 3 months for 12 months, and then every 6 months thereafter.
Scoring of Questionnaires. For the LCSS, a 100-mm VAS was used to score individual symptom severity, with 0 representing the best and 100 representing the worst possible score. The LCSS average symptom burden index (ASBI) (range 0-100) was calculated as the mean of the six symptom scores, with higher scores indicating greater symptom burden. The LCSS three-item global index (3-IGI) (range 0-300) was the sum of the scores for the three global items, with higher scores indicating reduced symptom burden. The minimally important difference (MID), the smallest change considered clinically meaningful, has been estimated to be a difference of 10 or more points in the ASBI score 28 and 30 or more points in the 3-IGI score.
For the EQ-5D, health state dimensions were scored by using three levels (no problems, some problems, or severe problems). The utility index score was scaled from 0 to 1, with higher scores indicating better health status, [24] [25] [26] and the VAS was scored on a 100-point vertical scale, with 0 representing the worst and 100 representing the best imaginable health state. The MID has been estimated to be a difference of 0.08 or more points for the utility index and seven or more points for the VAS. 24 Statistical Analysis. All randomized patients were included in the analysis of disease-related symptom improvement by week 12. All randomized patients with a PRO assessment at baseline and one or more assessments after baseline were included in other HRQoL analyses. The PRO questionnaire completion rate for each time point was calculated by using the number of patients with HRQoL data at baseline and the specific time point divided by the number of patients who were eligible for an assessment at that time point. For the LCSS ASBI, values were imputed for symptom-specific missing items by using values equal to the average of the nonmissing symptom-specific items if at least half the items were completed; if fewer than half were completed, data were treated as missing. For the other PRO measurements, no adjustments were made for missing data.
Changes from baseline PRO scores at each time point were evaluated by using descriptive statistics. Statistically significant (p 0.05) differences in PRO scores within and between treatment groups were assessed with t tests; clinically meaningful differences were determined per prespecified MIDs. Results were reported when assessments for five or more patients were available in the treatment group. Statistical significance in between-group changes were reported for 10 or more patients. Disease-related symptom improvement by week 12 was defined as a 10-point or more decrease from baseline in LCSS ASBI score at any time between randomization and week 12. The disease-related symptom improvement rate and its corresponding 95% exact confidence interval (CI) were calculated using the Clopper-Pearson method.
A mixed-effect model repeated measures analysis controlling for baseline covariates (PRO score and study stratification factors: region and prior paclitaxel use) assessed longitudinal HRQoL changes from baseline and differences between treatment groups during treatment. A Cox proportional hazards model was used to determine time from baseline to first deterioration in each PRO score (both during-treatment and posttreatment assessments) at the individual patient level, as defined by the MID for each measure.
Analyses were powered according to the efficacy end points for the trial; analyses of PROs were exploratory and not intended for hypothesis testing. All p values are presented for descriptive purposes to summarize the variation in the estimated effects.
Analyses were conducted using SAS software (version 9.4, SAS Institute, Cary, NC).
Results
Patients
In all, 272 patients were randomized to treatment with nivolumab (n ¼ 135) or docetaxel (n ¼ 137). 8 The median age was 63 years (range 39-85), and 76% of the patients were male; baseline characteristics were generally similar between treatment groups. 8 
PRO Questionnaire Completion Rates
The during-study completion rates for the LCSS and EQ-5D were comparable between treatment groups ( Supplementary Fig. 1 ). The LCSS completion rate at baseline was 77.8% in the nivolumab group and 76.6% in the docetaxel group; 68.9% and 62.8% of patients, respectively, completed the assessment at baseline and at one or more postbaseline visits. In both treatment groups, EQ-5D completion rates exceeded 70% up to week 12.
Analysis of PROs with the LCSS
The mean plus or minus SD LCSS ASBI scores at baseline were similar in the nivolumab (29.6 ± 16.4) and docetaxel (29.6 ± 14.7) groups. The proportions of patients exhibiting disease-related symptom improvement by week 12 were 20.0% (95% CI: 13.6-27.7) with nivolumab versus 21.9% (95% CI: 15.3-29.8) with docetaxel.
The during-treatment mean ASBI scores in the nivolumab group generally decreased (reduced symptom burden) over time, whereas scores in the docetaxel group generally increased ( Clinically meaningful improvements (!10 points) with nivolumab were observed from weeks 42 through 84. At week 60 and after week 66, the sample size decreased to fewer than 10 patients, making it difficult to interpret changes from baseline scores. Significant and clinically meaningful improvements were seen at various time points for five of the six LCSS symptoms (loss of appetite, fatigue, cough, dyspnea, and pain [Supplementary Table 1] ); changes in hemoptysis, the least common symptom, were small. In the docetaxel group, no significant changes in mean during-treatment ASBI scores from baseline were observed; at week 36, a clinically meaningful deterioration was seen, with only five patients noted to be evaluable in this group at that time.
Comparison of mean ASBI scores between treatment groups showed significant differences favoring nivolumab at weeks 30 (p ¼ 0.028) through 42 (p ¼ 0.018). Significant between-treatment group differences favoring nivolumab also were noted at week 42 for dyspnea, at weeks 36 through 48 for loss of appetite, and at weeks 36 through 54 for pain (see Supplementary Table 1) . Between-treatment group differences at week 24 and thereafter are difficult to interpret owing to the sparsity of data in the docetaxel group (n < 10).
At baseline, the mean plus or minus SD LCSS 3-IGI scores were 193.1 ± 63.0 in the nivolumab group and 192.7 ± 69.8 in the docetaxel group. The during-treatment mean 3-IGI scores in the nivolumab group generally increased (improved) over time, whereas scores in the docetaxel group decreased (Fig. 1B) . Significant improvements in mean scores were observed with nivolumab at week 24 (26.8 Only time points that had data available for five or more patients in either treatment group are shown. Minimally important differences consist of a change of 10 or more points for the LCSS average symptom burden index and 30 or more points for the LCSS three-item global index. Differences were compared by using t tests. *p < 0.05 versus baseline, shown for time points with 10 or more patients in either treatment group. † p < 0.05 for nivolumab versus docetaxel; shown for time points with 10 or more patients in either treatment group. ‡ Exceeded minimally important difference.
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HRQoL in Squamous NSCLC from CheckMate 01754 (p ¼ 0.002). At various time points, significant and clinically meaningful improvements in two of the three index items (symptom distress and HRQoL) were seen with nivolumab, whereas significant and clinically meaningful deteriorations in all three items were observed with docetaxel (Supplementary Table 2 ). Significant betweentreatment group differences favoring nivolumab were observed at weeks 30 through 54 for symptom distress and weeks 24 through 54 for HRQoL. As already noted, small samples sizes at later time points limit interpretation of within-and between-treatment group differences. After treatment discontinuation (follow-up visits 1 and 2), estimated changes from baseline in the LCSS ASBI and 3-IGI scores showed worsening in both treatment groups. For the ASBI, the estimated changes (range 5.5-9.5 points) were less than the MID and were significant only in the docetaxel group. For the 3-IGI, there was significant worsening in the nivolumab (follow-up visit 1 only) and docetaxel groups (both follow-up visits), with estimated changes greater than the MID in the docetaxel group. There were no significant betweentreatment group differences with either instrument after treatment discontinuation.
Analysis of PROs Using the EQ-5D
At baseline, mean plus or minus SD EQ-5D utility index scores were comparable in the nivolumab (0.683 ± 0.208) and docetaxel groups (0.663 ± 0.284). Duringtreatment mean utility index scores generally increased (improved health status) in the nivolumab group, whereas scores generally decreased in the docetaxel group (Fig. 2A) . Changes from baseline in utility index scores were not significant in the docetaxel group. As with the LCSS, clinically meaningful improvements (!0.08 points) with nivolumab were seen at weeks 42 through 66 and week 78; clinically meaningful worsening with docetaxel occurred at week 36. Significant differences in mean utility index scores between nivolumab and docetaxel groups were observed at weeks 48 (p ¼ 0.015) and 54 (p ¼ 0.030).
The mean plus or minus SD EQ-5D VAS scores at baseline were 63.7 plus or minus 18.2 in the nivolumab group and 66.3 plus or minus 20.5 in the docetaxel group. The during-treatment mean VAS scores increased (improved) over time with nivolumab and remained stable with docetaxel (Fig. 2B) clinically meaningful (!7 points) at weeks 24 through 48, 60 through 72, and 84. Significant betweentreatment group differences favoring nivolumab were seen at weeks 12 (p < 0.001) and 48 (p ¼ 0.037). As with the LCSS instrument, fewer than 10 patients completed EQ-5D questionnaires at week 60 and after week 66 in the nivolumab group and after week 18 in the docetaxel group.
After treatment discontinuation, the estimated changes from baseline in the EQ-5D utility index and VAS indicated worsening in both groups, with differences including values above and below the MID for both measures. There was only one significant difference (VAS in the docetaxel group: À10.5 [p ¼ 0.001]). The betweentreatment group differences were not significant.
The mean EQ-5D utility index scores during treatment with nivolumab or docetaxel were compared with those previously reported for a general U.S. population (N ¼ 11,248) by using data from the 2000 Medical Expenditure Panel Survey 29 and a population of patients with lung cancer who had participated in a validation study of cancer symptoms scales (N ¼ 50). 24 The mean utility index scores in the nivolumab group became more favorable than the mean score of a general U.S. population (0.8739) 29 beginning at week 42, whereas the scores in the docetaxel group were similar to the norm for a population with lung cancer (0.67) 24 ( Fig. 3A) . Likewise, the mean VAS scores in the nivolumab group exceeded the general population norm (80.05) 29 at weeks 48 and 60, but the scores in the docetaxel group were comparable with those in a population with lung cancer (68) 24 (Fig. 3B ).
Mixed-Effect Model Repeated Measures Analysis
Patients in the nivolumab group demonstrated significant improvements from baseline in LCSS ASBI, loss of appetite, fatigue, cough, and HRQoL scores and the EQ-5D utility index score, as well as a clinically meaningful improvement for cough (Table 1 ). In the docetaxel group, a significant improvement from baseline was observed for cough and a significant deterioration was observed for fatigue. Significant between-treatment group differences favoring nivolumab were identified for the LCSS ASBI, fatigue, LCSS 3-IGI, interference with activity level, HRQoL, and EQ-5D VAS.
Time to First Disease-Related Deterioration
Cox proportional hazards modeling (Fig. 4) showed that time to first disease-related deterioration for all LCSS and EQ-5D measures favored nivolumab (hazard ratio <1); between-treatment group differences were significant for LCSS loss of appetite, the LCSS 3-IGI and its individual items, and the EQ-5D utility index and VAS.
Deterioration in LCSS ASBI was later with nivolumab than with docetaxel, with the groups beginning to diverge at week 12; however, the difference was not significant (Fig. 5A) . Disease-related deterioration was significantly delayed with nivolumab versus with docetaxel on the basis of the LCSS 3-IGI, the EQ-5D utility index, and the EQ-5D VAS (Fig. 5B-D) .
Discussion
In CheckMate 017, which is the first randomized phase III trial specifically in second-line advanced squamous NSCLC, treatment with nivolumab provided superior OS versus treatment with docetaxel. 8 Here, we Only time points that had data available for five or more patients in either treatment group are shown. Minimally important differences consist of a change of 0.08 or more points for the EQ-5D utility index and seven or more points for the EQ-5D VAS. Differences were compared by using t tests. *p < 0.05 versus baseline; shown for time points with 10 or more patients in either treatment group. † p < 0.05 for nivolumab versus docetaxel, shown for time points with 10 or more patients in either treatment group.
‡ Exceeded the minimally important difference.
have reported that nivolumab-treated patients also experienced HRQoL and symptomatic benefits, as assessed by both lung cancer-specific and general health status PRO instruments. Because docetaxel has shown moderate OS and PRO benefits in similar patient populations in randomized clinical trials, 13, 14, 30, 31 its use as a comparator strengthens these analyses. Randomized phase III trials investigating combinations of targeted agents with docetaxel versus docetaxel alone as second-line therapy for advanced NSCLC showed improved OS with the combination regimens 32, 33 but not improvements or prolonged time to deterioration in PROs. 18, 19 CheckMate 017 is the first trial showing symptom and health status improvements and prolongation of time to deterioration with nivolumab versus with docetaxel.
Similar proportions of patients exhibited diseaserelated symptom improvement by week 12, as measured by the LCSS, with nivolumab versus with docetaxel. However, patients continuing treatment with nivolumab showed a mean reduction in symptom burden over time, whereas those continuing treatment with docetaxel experienced stabilization or worsening of symptoms. Importantly, nivolumab-treated patients demonstrated improvements in five of the six individual LCSS symptoms. These results are noteworthy because increased symptom severity in NSCLC has been linked to diminishing HRQoL 34 and is predictive of poor survival in patients with late-stage disease. 35 Because lung cancer is highly symptomatic, 9 the LCSS ASBI and 3-IGI may be particularly useful for measuring HRQoL and symptom impact in this population.
Equivalent trends were observed with the EQ-5D; patients continuing to take nivolumab showed improvement in health status, whereas those continuing to take docetaxel had stable or deteriorating health status. Of particular importance, at several later time points, the mean EQ-5D utility index and VAS scores in the nivolumab group surpassed those for a general U.S. population, 29 suggesting that prolonged treatment coincides with resumption of normal health status; EQ-5D utility index scores in the docetaxel group resembled those in a population with lung cancer 24 throughout treatment. Findings from the mixed-effect model repeated measures analysis supported improvements in HRQoL from baseline with nivolumab.
Cox proportional hazard modeling also identified improvement in HRQoL with nivolumab versus with docetaxel. After control for baseline covariates, significant differences in multiple HRQoL domains favoring nivolumab were retained, with significantly longer times to symptom deterioration in the nivolumab group versus in the docetaxel group.
These findings provide novel insights into HRQoL in patients with squamous NSCLC treated with nivolumab or docetaxel, as to date no randomized trials evaluating HRQoL in this population have been published. Nevertheless, limitations include the open-label nature of the study, slightly different timing of PRO evaluation between treatment groups; incomplete patient participation at all time points; and small sample sizes in the docetaxel group at later time points. Additionally, interpretation of the longitudinal analyses, which was limited to patients who continued to receive treatment, did not incorporate the patient experience after therapy discontinuation.
Beyond its established OS benefit and favorable safety profile in patients with advanced squamous NSCLC and disease progression after platinum-based chemotherapy, 8 the data reported here indicate that nivolumab alleviates symptom burden and improves health status compared with docetaxel. Although disease-related symptom improvement was similar with nivolumab and docetaxel at the prespecified 12-week analysis, clear improvements with nivolumab were evident at later time points, which may be related to its distinct mechanism of action. These conclusions are supported by data from two PRO instruments and a multistep analytical plan evaluating data descriptively, cross-sectionally, and longitudinally. These results suggest that patients receiving nivolumab as second-line treatment for squamous NSCLC can maintain or improve their HRQoL throughout their duration of therapy.
